论文部分内容阅读
目的探讨阿卡波糖联合维格列汀对2型糖尿病(T2DM)患者血糖控制及不良反应的影响。方法选取2015年3月至2017年2月大连市第五人民医院收治的86例T2DM患者为研究对象,按随机数字表法分为对照组(n=43)、试验组(n=43)。对照组患者予以阿卡波糖+瑞格列奈,试验组患者予以阿卡波糖+维格列汀,比较两组血糖控制[空腹血糖(FBG)、糖化血红蛋白(Hb A1c)、餐后2 h血糖(2 h PBG)]、BMI、胰岛β细胞功能相关指标[空腹血清C肽(FCP)、餐后2 h C肽(2 h FCP)、空腹胰岛素(FINS)、餐后2 h胰岛素(2 h FINS)]、不良反应。结果治疗后试验组患者FBG、2 h PBG、Hb A1c低于对照组,BMI高于对照组,差异均有统计学意义(均P<0.05);治疗后试验组患者2 h FCP、2 h FINS、FCP、FINS水平均高于对照组,差异均有统计学意义(均P<0.05);试验组患者不良反应发生率(14.0%)低于对照组(32.6%),差异有统计学意义(P<0.05)。结论阿卡波糖联合维格列汀可有效控制T2DM患者血糖水平,改善胰岛素β细胞功能,提高胰岛素抵抗能力,降低不良反应发生风险。
Objective To investigate the effects of acarbose combined with vildagliptin on glycemic control and adverse reactions in type 2 diabetes mellitus (T2DM). Methods Totally 86 T2DM patients treated in Dalian Fifth People ’s Hospital from March 2015 to February 2017 were selected as control group (n = 43) and experimental group (n = 43) according to random number table. Patients in the control group were treated with acarbose and repaglinide. The patients in the test group were treated with acarbose and vildagliptin. The levels of fasting blood glucose (FBG), HbA1c, (2 h PBG)], BMI, islet β cell function related indicators [fasting serum C peptide (FCP), 2 h postprandial C peptide (2 h FCP), fasting insulin (FINS), 2 h postprandial insulin 2 h FINS)], adverse reactions. Results After treatment, the FBG, 2 h PBG and Hb A1c in the experimental group were lower than those in the control group, and the BMI was higher than that in the control group (all P <0.05). After treatment, the 2 h FCP and 2 h FINS , FCP, FINS were higher than the control group, the difference was statistically significant (all P <0.05); the incidence of adverse reactions in the experimental group was 14.0% lower than that in the control group (32.6%), the difference was statistically significant P <0.05). Conclusion Acarbose combined with vildagliptin can effectively control the blood glucose level of T2DM patients, improve the function of insulin β cells, improve insulin resistance and reduce the risk of adverse reactions.